Effects of exercise on mitochondrial DNA content in skeletal muscle of patients with COPD by Puente Maestu, Luis et al.
Effects of exercise on mitochondrial DNA content in
skeletal muscle of patients with COPD
Luis Puente-Maestu,1,2 Alberto La´zaro,3 Alberto Tejedor,3 Sonia Caman˜o,3
Marta Fuentes,1,2 Miguel Cuervo,4 Beatriz Ola´iz Navarro,5 Alvar Agustı´6,7
ABSTRACT
Background Exhausting exercise reduces the
mitochondrial DNA (mtDNA) content in the skeletal
muscle of healthy subjects due to oxidative damage.
Since patients with chronic obstructive pulmonary
disease (COPD) suffer enhanced oxidative stress during
exercise, it was hypothesised that the mtDNA content
will be further reduced.
Objective To investigate the effects of exercise above
and below the lactate threshold (LT) on the mtDNA
content of skeletal muscle of patients with COPD.
Methods Eleven patients with COPD (6768 years;
forced expiratory volume in 1 s (FEV1) 4568%ref) and 10
healthy controls (6664 years; FEV1 9067% ref) cycled
45 min above LT (65% peak oxygen uptake (V9O2peak)
and another 7 patients (6566 years; FEV1 5064%ref)
and 7 controls (5669 years; FEV1 9266%ref) cycled
45 min below their LT (50% V9O2peak). Biopsies from the
vastus lateralis muscle were obtained before exercise,
immediately after and 1 h, 1 day and 1 week later to
determine by PCR the mtDNA/nuclear DNA (nDNA) ratio (a
marker of mtDNA content) and the expression of the
peroxisome proliferator-activated receptor-gcoactivator-1a
(PGC-1a) mRNA and the amount of reactive oxygen
species produced during exercise was estimated from
total V9O2.
Results Skeletal muscle mtDNA/nDNA fell significantly
after exercise above the LT both in controls and in patients
with COPD, but the changes were greater in those with
COPD. These changes correlated with production of
reactive oxygen species, increases in manganese
superoxide dismutase and PGC-1a mRNA and returned to
baseline values 1 week later. This pattern of response was
also observed, albeit minimised, in patients exercising
below the LT.
Conclusions In patients with COPD, exercise enhances
the decrease in mtDNA content of skeletal muscle and the
expression of PGC-1a mRNA seen in healthy subjects,
probably due to oxidative stress.
INTRODUCTION
Exercise limitation is a frequent complaint of
patients with chronic obstructive pulmonary
disease (COPD) and a major precipitator of their
poor health status. Several cellular and molecular
alterations that can contribute to exercise limita-
tion have been described in the skeletal muscle of
these patients.1e7 Our group has recently identiﬁed
several mitochondrial abnormalities, including
malfunction of the electron transport chain,
abnormal kinetics of the mitochondrion perme-
ability transition pore and excessive production of
reactive oxygen species (ROS),8 9 that can also
contribute to exercise limitation and skeletal
muscle dysfunction in COPD.
In healthy subjects, fatiguing exercise causes
a reduction in the mitochondrial DNA (mtDNA)
content of skeletal muscle due to oxidative damage
whereas low-intensity non-fatiguing exercise does
not.10 This has not been investigated in patients
with COPD but, because mitochondrial ROS
production is augmented in such patients,8 11e13
we hypothesised that the fall in mtDNA content
reported in healthy subjects10 will be enhanced in
patients with COPD, particularly during fatiguing
exercise above their lactate threshold (LT). Accord-
ingly, this study sought to compare the dynamic
changes induced by two types of exercise protocols
(above and below the LT) in mtDNA content of the
vastus lateralis muscle in patients with COPD and
healthy controls. To get an insight into the poten-
tial molecular mechanisms, we also investigated
the amount of ROS produced during exercise, the
dynamic changes in the activity of manganese
superoxide dismutase (MnSOD; EC 1.15.1.1),
a major antioxidant enzyme, and of the expression
of peroxisome proliferator-activated receptor-g
coactivator-1a messenger RNA (PGC-1a mRNA),
a master regulator of mitochondrial biogenesis14
which appears to be abnormal in COPD.6 A better
understanding of mitochondrial changes induced
by exercise in the skeletal muscle of patients with
COPD may be helpful for the design of improved
rehabilitation strategies.
METHODS
Population
Patients with COPD (diagnosis according to the
GOLD guidelines15) had moderate to severe airﬂow
limitation (forced expiratory volume in 1 s (FEV1)
<65% reference value), declared to have ceased
smoking at least 6 months before enrolling, had not
participated in a rehabilitation programme before
and had no contraindication for exercise testing.
Controls were non-smoking subjects with normal
aerobic capacity and resting pulmonary function
without any obvious lung, cardiac or other major
disease after reviewing their medical information.
Study design
This is a prospective and controlled study. To
determine peak oxygen uptake (V9O2peak), all
participants performed an incremental (20 W/
min) symptom-limited exercise test on a cycle
ergometer (ER-900, Jaeger, Hochberg, Germany)
with continuous monitoring of oxygen saturation
(Nellcor N-180, Pleasanton, California, USA) and
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breath-by-breath measurements of ventilation and pulmonary
gas exchange (Quark-b2 system, Cosmed, Rome, Italy). Those
who developed severe hypoxaemia (SaO2 <87%) during the
incremental test were excluded from further investigations.
Then, 1e2 weeks later, the effects of two constant exercise
protocols, above and below the LT, were investigated. The
former entailed 3 min resting, 3 min unloaded pedalling and
a total of 45 min pedalling (60 rpm) at 65% of V9O2peak whereas
the latter entailed pedalling (60 rpm) at 50% of V9O2peak during
45 min. An arterial blood sample was anaerobically drawn
immediately after exercise and analysed for blood gases and
lactate concentration (Synthesis 1740, Instrumentation Labora-
tory, Lexington, Massachusetts, USA). Different subjects
participated in the two exercise protocols (table 1) because of the
high number of muscle biopsies needed (see limitations).
Patient characterisation
Spirometry was determined in the seated position with
a Masterscope-PFT system (VYASIS, Hochberg, Germany);
reported values correspond to those measured 15 min after the
inhalation of 200 mg salbutamol. Fat-free mass was measured by
bioelectrical impedance (Bodystat 1500, Bodystat Ltd, Douglas,
Isle of Man, UK).
Muscle biopsies
Biopsies from the vastus lateralis muscle were obtained with an
18G Tru-Cut biopsy needle (Cardinal Health-España, Madrid,
Spain) 2e7 days before the exercise test, immediately after it,
and 1 h, 24 h and 1 week later. Two patients with COPD and
three controls refused to be biopsied 1 week after exercise. The
biopsy specimens were immediately frozen and stored at 808C
until analysis.
PCR measurements
To estimate the mDNA content we quantiﬁed the mtDNA to
nuclear DNA (nDNA) ratio (mtDNA/nDNA). Total DNA was
extracted (QIAGEN GmbH, Hilden, Germany) and quantitated
spectrophotometrically. The mtDNA content was measured by
PCR (ABI Prisma 7700, Perkin-Elmer, California, USA) and
corrected by the simultaneous measurement of a single copy
nuclear RNAseP gene. Primers used for the analysis of mtDNA
were mt806F (59-CCACGGGAAACAGCAGTGATT-39) and
mt929R (59-CTATTGACTTGGGTTAAT CGTGTGA-39). The
TaqMan probe was labelled at the 59 end with the ﬂuorescent
dye FAM (59TGCCAGCCACCGCG-39). To quantify nDNA we
used a commercial kit (PDARs RNAseP; Applied Biosystems,
Carlsbad, CA, USA) and a nDNA-speciﬁc ﬂuorescent probe
labelled internally using the ﬂuorescent dye VIC. PCR condi-
tions were 2 min at 508C and 10 min at 958C, followed by 40
cycles of 15 s of denaturation at 958C and 60 s of annealing/
extension at 608C. Data are expressed as the mean of three
measurements.
The amount of PGC-1amRNAwas also quantiﬁed by PCR (ABI
Prisma 7700, Perkin-Elmer, Foster City, California, USA). The
Table 1 Characteristics of the study population
Above LT Below LT
Controls (n[10) COPD (n[11) Controls (n[7) COPD (n[7)
Clinical data
Age (years) 66.564.3 67.268.4 56.768.9 65.066.5
BMI (kg/m2) 26.262.4 24.863.2 27.367.0 25.762.5
FFMI (kg/m2) 21.062.6 19.261.4 22.465.3 19.361.8
Lung function and peak exercise data
FEV1 (l) 2.960.4 1.460.3*** 2.860.5 1.660.3***
FEV1 (% ref) 90.366.8 44.867.7*** 92.565.6 49.963.8***
TLCO (% ref) 89.1612.4 56.7616.1** 91.466.5 63.968.7**
PaO2 at rest (mm Hg) 7767 6767** 8363 6665***
V9O2peak (l/min) 1.6760.23 1.2360.18** 1.7360.34 1.3460.29*
V9O2peak (% ref) 9163.3 68610.4*** 9062.3 71611.9**
V9O2 at LT (l/min) 1.0360.13 0.7360.15** 0.8260.10 1.0660.26**
Work rate peak (W) 132 623 88617** 143635 99627*
V9Epeak (l/min) 64.969.3 48.164.1*** 74.9616.2 53.8616.5**
Skeletal muscle results at rest
mtDNA/nDNA 12416184 11046183 12276210 10826229
PGC-1a mRNA (arbitrary units) 1.0260.12 0.8660.44 0.9960.24 0.7660.16
MnSOD (U/mg) 1.1060.37 1.5360.51* 0.960.2 1.3360.39*
Constant work load exercise data
Work rate (W) 86614 57625*** 72620 50614**
V9O2peak (l/min) 1.5560.14 1.1360.26** 0.8360.19 0.6560.15*
V9Epeak (l/min) 61.365.7 44.665.9** 36.769.1 27.968.5*
End exercise dyspnoea, CR10 5.062.2 4.161.4 3.661.8 2.061.0
End exercise leg fatigue, CR10 7.561.8 6.861.6 4.762.1 2.461.5*
Total V9O2 (mmol) 21226280 15156227*** 11136223 8656187***
Estimated ROS production (mmol/kg) 0.7660.15 1.4560.24*** 0.460.1 0.8160.16***
PaO2 peak exercise (mm Hg) 8064 6666*** 8765 6767***
Lactate end (mEq/l) 5.460.7 5.060.6 2.460.3 2.860.5
Values shown are mean6SD.
*p<0.05; **p<0.01; ***p<0.001 vs controls.
BMI, body mass index; CR10, Borg CR10 scale; FEV1, forced expiratory volume in 1 s; FFMI, fat-free mass index; LT, lactate threshold; MnSOD, manganese superoxide dismutase; mtDNA,
mitochondrial DNA; nDNA, nuclear DNA; PaO2, arterial oxygen tension; % ref, percentage of predicted values; PGC-1a, peroxisome proliferator-activated receptor-gcoactivator-1a; ROS, reactive
oxygen species; TLCO, carbon monoxide transfer factor; V9O2 oxygen uptake; V
9
E, minute ventilation.
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forward and reverse primers employed were 59-CACTTA-
CAAGCCAAACCAA
CAACT-39 and 59-CAATAGTCTTGTTCTCAAATGGGGA-39,
respectively. Values were expressed relative to the mean data
obtained in controls at rest before exercise.
Oxidative stress
The mtDNA oxidation assay used is based on two premises16:
(1) oxidative DNA damage blocks the progression of polymerase
and causes decreased DNA ampliﬁcation; and (2) the probability
of oxidative lesions is lower in shorter DNA segments. Thus, the
ratio between the ampliﬁcation of a short (8.9 kb) and a long
(207 kb) fragment (relative ampliﬁcation; RA) is a marker that
mirrors mtDNA oxidation (ie, the lower RA value the higher
mtDNA oxidation16). The two mtDNA fragments ampliﬁed
were for the 8.9 kb fragment: mt5999F (5-TCTAAGCCTCC
TTATTCGAGCCGA-3) and mt14841R (5-TTTCATCATGCG-
GAGATGTTGG ATGG-3) and the 207 bp fragment: mt4181F
(5-ACTTCCTACCACTC ACCCTA-3) and mt4388R
(5-TGATAGGTGGCACGGACAAT-3). PCR was performed as
described above and the mean resting value of RA in control
subjects was considered the reference value (100% RA).
The amount of ROS produced during exercise was estimated
assuming that, in healthy subjects, 2% of mitochondrial V9O2 is
diverted into the generation of ROS17 and that this is 2.5 times
greater in patients with COPD.8
Finally, the activity of MnSOD in skeletal muscle biopsies was
measured by the inhibition of nitroblue tetrazolium conversion
by MnSOD into a blue tetrazolium salt method (Sigma-Aldrich,
St Louis USA), as described by Beauchamp and Fridovich.18
Statistical analysis
The results are presented as mean6SD unless speciﬁed other-
wise. Comparisons between groups were performed using the
paired t test or two-way ANOVA with two factors (group and
time), as appropriate. Contrasts at speciﬁc time points were
made by the unpaired t test. Correlations between variables of
interest were explored with the Pearson linear correlation coef-
ﬁcient. A p value <0.05 was considered signiﬁcant.
RESULTS
The main results are summarised in table 1. Age, body mass
index and free fatty mass index were similar between groups.
Airﬂow limitation was moderate to severe in patients with
COPD whereas spirometry was normal in controls. Patients
with COPD had moderate hypoxaemia. Aerobic capacity
(V9O2peak) was normal in controls and moderately reduced in
patients with COPD (table 1). Resting MnSOD concentrations
were signiﬁcantly higher in patients with COPD than in
controls (table 1). At rest, when all the patients with COPD
were compared with all controls, mtDNA/nDNA and PGC-1a
values were signiﬁcantly lower in the former (mtDNA/nDNA:
10966196 vs 12366189, p¼0.039; PGC-1a: 0.08160.33 vs
1.0160.17, p¼0.035). However, the differences did not reach
statistical signiﬁcance when analysed separately by groups
according to the speciﬁc type of constant exercise test to which
they had been allocated (table 1).
Exercise above LT
To complete a total of 45 min pedalling at 65% of their
V9O2peak, six patients had to stop twice and three patients three
times (all because of leg fatigue) whereas three completed the
test at once without stopping. Likewise, four controls stopped
once (because of leg fatigue) and six did it without stopping. No
patient or control subject reached their V9O2peak at any time
during the constant work rate exercise challenge. Lactate levels
after exercise were similar in both groups (table 1) and indicate
that the intensity of the effort was well above the LT (table 1).
mtDNA/nDNA declined after exercise both in controls and
patients with COPD but the changes were larger (p¼0.02) in
patients with COPD (ﬁgure 1, upper panel). As a result,
immediately after exercise mtDNA/nDNA had decreased by
e246699 in patients with COPD compared with 167649 in
controls (p¼0.036), whereas these ﬁgures were, respectively,
4246147 vs 277666 1 h after exercise (p¼0.009) and
3676218 vs 1946110 24 h later (p¼0.036). One week after
exercise (ﬁgure 1, upper panel) mtDNA/nDNA had recovered
baseline values in both groups (12691 vs 426105, p¼0.55). By
contrast, the concentration of MnSOD tended to increase after
exercise in parallel in both groups (ﬁgure 2, upper panel), the
changes reaching statistical signiﬁcance 24 h after exercise
(p¼0.011 and p¼0.014 for patients with COPD and control
subjects, respectively) and returning to baseline levels 1 week
later. During this time course, differences in MnSOD observed at
rest between patients and controls groups were basically
unchanged throughout (ﬁgure 2, upper panel).
PGC-1a mRNA levels at rest (table 1) tended to be reduced in
patients with COPD (p¼0.07). After exercise (ﬁgure 3, upper
panel) they increased in both groups to a similar extent (ﬁgure 3
upper panel), but the changes were signiﬁcantly higher
(p¼0.038) in patients with COPD 1 h after exercise (ﬁgure 3,
upper panel). By 24 h of recovery, PGC-1a mRNA levels were
repressed and corresponded to levels observed at rest (ﬁgure 3,
upper panel).
Exercise below LT
The lactate concentration at the end of exercise did not reach
3 mEq/l, conﬁrming that the intensity of exercise was below the
LT (table 1). As shown in ﬁgure 1 (lower panel), low intensity
exercise also induced signiﬁcant changes in mtDNA/nDNAwith
respect to baseline in patients with COPD (109694
Figure 1 Time course of mean6SEM changes in mitochondrial DNA/
nuclear DNA (mtDNA/nDNA) in controls (closed circles) and patients
with chronic obstructive pulmonary disease (COPD) (open circles)
exercising at high intensity (upper panel) and low intensity (lower panel).
*p<0.05; **p<0.01; ***p<0.001 isotime COPD vs controls. LT, lactate
threshold.
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immediately after exercise, p¼0.048; 220691 1 h later, p¼0.06;
and 1596213 after 24 h, p¼0.014), but not in controls
(33644, p¼0.12 immediately after exercise; 736205, p¼0.38
1 h later; and 33694 after 24 h, p¼0.39). It should be noted
also that absolute mtDNA/nDNA changes were smaller when
patients with COPD exercise below the LT than above it
(p¼0.007, p¼0.024, p¼0.004 and p¼0.131, respectively, for
intergroup comparisons at the end of the exercise and 1 h, 24 h
and 1 week later; ﬁgure 1). On the other hand, the MnSOD
concentration was basically constant after exercise below the LT,
so differences with controls were maintained through time
(ﬁgure 2, lower panel) whereas changes in PGC-1a mRNA were
still evident in patients with COPD but absent in controls
(ﬁgure 3, lower panel).
Potential associations
Because previous studies in healthy subjects ascribed a key
pathogenic role to oxidative stress in the observed decrease in
the mtDNA content in skeletal muscle,10 we explored potential
relationships between the estimated production of ROS during
exercise and changes from rest to 1 h after exercise in mtDNA/
nDNA in the entire population of subjects (patients and
controls) studied both above and below the LT (ﬁgures 4 and 5).
Our data conﬁrm that a higher production of ROS during
exercise was associated with a signiﬁcant decrease in mRNA/
nDNA (ﬁgure 4A) and a larger change in MnSOD (ﬁgure 4C).
Furthermore, we found a good correlation between the esti-
mated ROS production and mtDNA relative ampliﬁcation
(ﬁgure 4B), suggesting that the former is a reasonably good
proxy of the amount of oxidative stress during exercise.
On the other hand, we extended previous observations by
showing that the estimated ROS production during exercise was
also associated with a signiﬁcant increase in PGC-1a mRNA 1 h
after exercise (ﬁgure 4D). Likewise, we observed signiﬁcant
correlations between the total amount of oxygen consumed per
kg of fat-free mass during exercise and these same muscle vari-
ables (ﬁgure 5). Finally, we found that changes in PGC-1a
mRNA were also signiﬁcantly related to changes in mtDNA/
nDNA (r¼0.52, p<0.001) and MnSOD (r¼0.40, p¼0.017) (data
not shown).
DISCUSSION
Our results conﬁrm that, in healthy subjects, fatiguing exercise
induces a fall in skeletal muscle mtDNA content10 and upregu-
lates PGC-1a mRNA expression.14 19 We extend these observa-
tions for the ﬁrst time to patients with COPD where, as
hypothesised, changes are enhanced (ﬁgures 1 and 3), probably
in relation to augmented oxidative stress (ﬁgures 4 and 5). We
also highlight the different recovery dynamics of PGC-1amRNA
expression and mtDNA changes; the former returns to normal
values 24 h after exercise (ﬁgure 3) whereas the latter takes
longer to recover (ﬁgure 1). Our results also show that these
effects are less marked when patients exercise below the LT
(ﬁgures 1e3).
Previous studies
A number of cellular and molecular abnormalities have been
described in the skeletal muscle of patients with COPD1 4 20 21
including mitochondrial changes.1 3 5 8 9 The lower PGC-1a
mRNA expression observed in skeletal muscle biopsies of
patients with COPD at rest are in keeping with these previous
observations and may be the consequence of inactivity or
a switch towards type II ﬁbres (known to express less PGC1a-
mRNA and reported in COPD).1 8 20 21 To our knowledge,
however, this is the ﬁrst study that has speciﬁcally investigated
the effects of exercise, both below and above the LT, on these
markers in these patients. Overall, the pattern of response to
exercise of mDNA/nDNA and PGC-1a mRNA observed in
patients with COPD is similar to that described in healthy
subjects10 14 19 but, for a given exercise intensity, mDNA/nDNA
changes are magniﬁed in COPD (ﬁgures 1 and 3).
Potential mechanisms
At rest the mtDNA/nDNA ratio was lower in patients with
COPD. This is consistent with several abnormalities previously
Figure 2 Time course of mean6SEM changes in manganese
superoxide dismutase (MnSOD) in controls (closed circles) and patients
with chronic obstructive pulmonary disease (COPD) (open circles)
exercising at high intensity (upper panel) and low intensity (lower panel).
*p<0.05 isotime COPD vs controls. LT, lactate threshold.
Figure 3 Time course of mean6SEM changes in peroxisome
proliferator-activated receptor-gcoactivator-1a (PGC-1a) in controls
(closed circles) and patients with chronic obstructive pulmonary disease
(COPD) (open circles) exercising at high intensity (upper panel) and low
intensity (lower panel). *p <0.05; ***p <0.001 isotime COPD vs
controls. LT, lactate threshold.
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described in these patients including decreased density of
mitochondria in the vastus lateralis muscle,3 reduced citrate
synthase activity4 8 21 22 and/or a higher proportion of type II
ﬁbres1 with less oxidative capacity and lower PGC-1a-mRNA
expression23 (as was also observed in our patients).
We conﬁrmed that the mtDNA content decreases in healthy
subjects after fatiguing exercise10 24 and we show for the ﬁrst
time that this is enhanced in patients with COPD. As previously
suggested,10 24 our results support a pathogenic role of oxidative
stress because: (1) it is well established that patients with COPD
produce a larger amount of ROS than healthy controls during
exercise11e13 24; (2) we found both temporal and statistical
correlations between the estimated ROS burden produced
during exercise and changes in mtDNA content (ﬁgure 4); (3) we
observed a biological gradient between the expected ROS
production and the changes in mtDNA/nDNA that were
reduced in patients with COPD exercising below their
LT (ﬁgure 1) who also have less oxidative stress (table 1 and
ﬁgures 4 and 5); (4) the fall in mtDNA after exercise was related
to changes in MnSOD concentration and PGC-1a mRNA
content (ﬁgure 4), both known to be related to oxidative
stress22 25; and (5) it is biologically plausible that, as the main
subcellular site of ROS production is the mitochondria,26 27 the
concentration of ROS in the mitochondrial matrix is 5e10-fold
higher than in the cytosol or nucleus and the level of oxidised
bases in mtDNA is 10e20-fold higher than in nDNA.28 In
addition, unlike nDNA, mtDNA lacks protective histones26 and
is endowed with relatively low DNA repair activity.26 It is
therefore entirely plausible29 that enhanced ROS production
during exercise in the skeletal muscle of patients with COPD
may contribute to amplifying the decrease in mtDNA in these
patients (ﬁgures 1 and 4). Together these arguments support
a mechanistic role for oxidative stress in the enhanced decrease
in mtDNA content in the skeletal muscle of patients with
COPD after exercise.
Clinical implications
Our observations may be relevant for rehabilitation programmes
in COPD because oxidative mtDNA damage and PGC-1a mRNA
expression are prerequisites for adaptation to training.10 19 22 30 In
this context it is noteworthy that moderate intensity exercise
(below the LT) induced both a signiﬁcant decrease in mtDNA/
nDNA and an increase in PGC-1a mRNA expression in the
patients with COPD.
Figure 4 Correlation between estimated production of reactive oxygen species (ROS) during exercise and changes from rest to 1 h after exercise in
(A) mitochondrial DNA/nuclear DNA (mtDNA/nDNA) ratio, (B) mtDNA oxidative damage (relative amplification), (C) manganese superoxide dismutase
(MnSOD) and (D) peroxisome proliferator-activated receptor-gcoactivator-1a (PGC-1a) mRNA in controls (closed symbols) and patients with chronic
obstructive pulmonary disease (COPD) (open symbols) studied both above (circles) and below the lactate threshold (triangles). FFM, fat-free mass.
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The response of PGC-1a mRNA to exercise indicates that, at
least in the patients with COPD studied here who were not
characterised by a low body mass index (table 1), the ﬁrst step
for mitochondrial biogenesis and type I ﬁbre differentiation is not
altered22 and that, consequently, other mechanisms should be
implicated in the pathobiology of muscle atrophy in COPD.1 31
This observation also raises concerns about the potential utility of
antioxidant supplementation during rehabilitation as they could
dampen ROS signalling and interfere with mitochondrial
biogenesis.22
Potential limitations
Some potential limitations of our study deserve discussion. First,
the sample size was relatively small and biopsy specimens were
not available 1 week after exercise in a few subjects. However,
we believe that our results are valid because they were internally
consistent within each group. Second, different subjects partic-
ipated in the two exercise protocols (below and above the LT)
because the considerable number of biopsies involved in the
study precluded other alternatives. However, the baseline char-
acteristics of the patients and controls in both protocols were
similar (table 1) and the biological response of healthy subjects to
exercise, both above and below the LT, was similar to that
previously described. Third, ROS production during exercise was
not measured directly but was estimated from published data.8 17
However, we think that the correlation observed with several
independent variables such as mtDNA/nDNA, MnSOD and
oxidised mtDNA support our interpretation of the results. Finally,
patients with COPD were treated with b2 agonists but these
drugs do not appear to inﬂuence mitochondrial biogenesis signals,
including PGC-1a.32
Conclusions
Our study shows that exercising at the typical intensity and
duration of training sessions in pulmonary rehabilitation
programmes produces a signiﬁcant decrease in the mtDNA
content of skeletal muscle in patients with COPD and over-
expression of PGC-1a mRNA, probably in relation to enhanced
oxidative stress. Interestingly, the changes are minimised but
not abolished with non-fatiguing exercise below the LT, and this
may be relevant for the training effect seen in these patients
training below the LT.
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Lung alert
Lactate clearance is not inferior to central venous
oxygen saturation as a goal in early sepsis resuscitation
Goal-directed therapy in severe sepsis improves outcome by providing protocol-driven targets
for initial resuscitation. Current guidelines use central venous oxygen saturations (ScvO2) to
assess oxygen delivery and metabolism, but this requires specialist equipment and expertise
which may limit its use. This study addresses whether a change in serum lactate
concentration may act as an alternative.
This prospective multicentre trial randomised 300 patients with severe sepsis or septic
shock to one of two resuscitation protocols. Initially, central venous pressure and mean
arterial pressure were normalised using crystalloid boluses and vasopressors. Red blood cell
transfusion and dobutamine were then used to either achieve a target ScvO2 of >70% or
a lactate clearance of 10% within the ﬁrst 2 h of resuscitation.
There was no signiﬁcant difference in absolute in-hospital mortality between the two
groups (34 patients (23%) died in the ScvO2 group vs 25 (17%) in the lactate clearance group).
There was no difference in treatment-related adverse events. Only 29 patients received a blood
transfusion or dobutamine to achieve these targets.
This study shows that lactate clearance is a simple but effective measure of total body
oxygen metabolism which may be comparable to ScvO2 when resuscitating patients with
severe sepsis. However, this study was not blinded and was performed in hospitals with
established goal-directed sepsis protocols and hence may not be generalisable to other
institutions.
< Jones AE, Shapiro NI, Trzeciak S, et al. Lactate clearance versus central venous oxygen saturation as goals of early sepsis
therapy: a randomized clinical trial. JAMA 2010;303:739e46.
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